Close Menu

NEW YORK (GenomeWeb) – Roche today announced the final results of its tender offer to purchase up to 15.6 million shares of common stock of Foundation Medicine at $50 per share, after disclosing preliminary results last week.

Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock. Because the offer was oversubscribed, Roche will accept 83.2 percent of shares offered by each tendering stockholder for purchase.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.